Status:
ACTIVE_NOT_RECRUITING
The Global cVAD Study
Lead Sponsor:
Abiomed Inc.
Collaborating Sponsors:
Beth Israel Deaconess Medical Center
Yale University
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
Brief Summary
The intent of the Global cVAD Study is to utilize observational data of the ABIOMED, Inc. hemodynamic support devices in real-world settings to drive best practice usage patterns identified through st...
Detailed Description
Ongoing, observational, multicenter, records review of patients receiving the ABIOMED, Inc. hemodynamic support device(s). To collect in-hospital data, a waiver of consent and authorization will be re...
Eligibility Criteria
Inclusion
- 1\. All subjects in the study population are eligible for enrollment at the time of receiving support from an ABIOMED, Inc. hemodynamic support device, or at the time of attempt to implant an ABIOMED, Inc. hemodynamic support device.
Exclusion
- 1\. Patients in whom an attempt to implant an ABIOMED, Inc. hemodynamic support device did not occur.
Key Trial Info
Start Date :
July 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
20000 Patients enrolled
Trial Details
Trial ID
NCT04136392
Start Date
July 14 2017
End Date
January 1 2026
Last Update
May 10 2021
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Banner Health Research Institute, Banner Good Samaritan Hospital
Phoenix, Arizona, United States, 85006
3
Banner University Medical Center
Tucson, Arizona, United States, 85724
4
University of Southern California Keck Hospital
Los Angeles, California, United States, 90033